Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical Co's quarterly common stock
stayed the same
from Sep. 2025 (円23,853 Mil) to Dec. 2025 (円23,853 Mil) and
stayed the same
from Dec. 2025 (円23,853 Mil) to Mar. 2026 (円23,853 Mil).
Kaken Pharmaceutical Co's annual common stock
stayed the same
from Mar. 2024 (円23,853 Mil) to Mar. 2025 (円23,853 Mil) and
stayed the same
from Mar. 2025 (円23,853 Mil) to Mar. 2026 (円23,853 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (TSE:4521) has a Common Stock of 円23,853 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Common Stock too high?
Kaken Pharmaceutical Co's current Common Stock is 円23,853 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Common Stock compare to ZTS?
Kaken Pharmaceutical Co's Common Stock of 円23,853 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Common Stock is 円23,853 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,974.43, compared to a current price of 円4,015.00 — trading 1% above its estimated fair value. The current Common Stock is 円23,853 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Common Stock is 円23,853 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円4,015.00 is trading 1% above its estimated GF Value™ of 円3,974.43.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
Common Stock: 円23,853 Mil
GF Value™: 円3,974.43 vs. price of 円4,015.00 (1% above fair value)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
62GF Score
Get the complete analysis for TSE:4521
Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
